BillionToOne, Inc. (BLLN) vs Dianthus Therapeutics, Inc. (DNTH)
A side-by-side comparison of BillionToOne, Inc. and Dianthus Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BLLN
BillionToOne, Inc.
$102.02HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
DNTH
Dianthus Therapeutics, Inc.
$84.49HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Total return — BLLN vs DNTH
growth of $100 · dividends reinvested · last 1yBLLN +0.1% (+0.1%/yr)DNTH +161.0% (+161.0%/yr)DNTH compounded faster over this window
BLLN DNTH
BLLN vs DNTH: by the numbers
- •DNTH is the larger company ($4.73B vs $4.69B market cap).
- •BLLN is profitable (8.43% net margin) while DNTH runs a net loss (-1570.85%).
Metrics side by side
Valuation
| Metric | BLLN | DNTH |
|---|---|---|
| P/E ratio | 164.52 | N/A |
| Forward P/E | 128.44 | N/A |
| P/S ratio | 11.81 | 2482.09 |
| P/B ratio | 8.74 | 4.03 |
| EV / EBITDA | 77.12 | N/A |
| FCF yield | 0.71% | N/A |
Profitability
| Metric | BLLN | DNTH |
|---|---|---|
| Gross margin | 71.27% | 96.01% |
| Operating margin | 10.90% | -8739.34% |
| Net margin | 8.43% | -1570.85% |
| ROE | 6.24% | -2.55% |
| ROIC | 6.39% | -18.48% |
Growth (annualized)
| Metric | BLLN | DNTH |
|---|---|---|
| Total return CAGR (5Y) | N/A | -5.50% |
Frequently asked
- Is BLLN or DNTH more profitable?
- BLLN runs the higher net margin — BLLN at 8.43% versus DNTH at -1570.85%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.